Reproductive medicine and biology · 2025
Chitosan/Alginate-Loaded Astragalus hamosus Shows Ameliorative Effects on Lipid Profile, Inflammatory and Hormonal Parameters, and Reduces miRNA-222 Expression in Polycystic Ovary Syndrome Rats.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jafardoust Rashid, Parvini Kohneh Shahri Maryam, Ghazi Tabatabaei Zohreh, Pouryaee Ata
Аннотация
PURPOSE: This study investigated the therapeutic effects of Chitosan/Alginate-loaded Astragalus hamosus extract (Chn/Al-AH) on the expression of miRNA-222 and ESR1 genes, inflammatory cytokines, lipid profile, and reproductive hormones in a rat model of polycystic ovary syndrome (PCOS) induced by estradiol valerate (EV).
METHODS: Twenty-five female Wistar rats, weighing an average of 180 g, were divided into control and PCOS groups. The PCOS model was induced by a single intramuscular injection of EV (4 mg/kg). After 28 days of PCOS induction, the rats were orally administered Chitosan/Alginate-loaded AH at 5, 10, and 15 mg/kg. Following 4 weeks of treatment, histological and biochemical parameters, pro-inflammatory cytokines, body weight, and the expression of miRNA-222 and ESR1 genes were evaluated.
RESULTS: EV-induced PCOS rats showed increased body weight, dyslipidemia, elevated inflammatory cytokines, disrupted sex hormone levels, upregulation of miRNA-222, and decreased ESR1 expression. Treatment with Chn/Al-AH significantly ameliorated these alterations by improving metabolic and endocrine profiles, reducing miRNA-222 expression, enhancing follicular development, decreasing cystic follicles, and promoting corpus luteum formation.
CONCLUSIONS: Chn/Al-AH demonstrates therapeutic potential in mitigating hormonal, inflammatory, and genetic disruptions associated with PCOS in rats.
METHODS: Twenty-five female Wistar rats, weighing an average of 180 g, were divided into control and PCOS groups. The PCOS model was induced by a single intramuscular injection of EV (4 mg/kg). After 28 days of PCOS induction, the rats were orally administered Chitosan/Alginate-loaded AH at 5, 10, and 15 mg/kg. Following 4 weeks of treatment, histological and biochemical parameters, pro-inflammatory cytokines, body weight, and the expression of miRNA-222 and ESR1 genes were evaluated.
RESULTS: EV-induced PCOS rats showed increased body weight, dyslipidemia, elevated inflammatory cytokines, disrupted sex hormone levels, upregulation of miRNA-222, and decreased ESR1 expression. Treatment with Chn/Al-AH significantly ameliorated these alterations by improving metabolic and endocrine profiles, reducing miRNA-222 expression, enhancing follicular development, decreasing cystic follicles, and promoting corpus luteum formation.
CONCLUSIONS: Chn/Al-AH demonstrates therapeutic potential in mitigating hormonal, inflammatory, and genetic disruptions associated with PCOS in rats.